Table 2.

Characteristics of studies included in systematic review.

Year, author	Study design	Underlying disease	Study population	Intervention	Mortality rate (%)	Control	Mortality rate (%)	p value	Diagnostic criteria	Quality of study	Result
Tang et al., 2020	Retrospective cohort study	COVID-19-sepsis	97	LMWH-heparin	40	No heparin exposure	64.2	0.029	ISTH	Good	Effective
Mant and King, 1979	Retrospective cohort study	Infections, shock, trauma, hepatic disease, malignancy	47	Heparin	83	No heparin exposure	86	>0.05	OC	Poor	Neutral
Sakuragawa et al., 1993	Randomized controlled clinical trial	Malignant tumor, Infection, Vascular disease, gynecologic disease, surgical disease, burn	124	LMWH (Dalteparin)	0	Heparin	7.8	NS	JMHW	FIGURE 2	Effective
Wen et al., 2018	Randomized controlled clinical trial	Trauma	77	LMWH/heparin	19.2/24	Coagulation factors only	57.7	<0.05/<0.05	ISTH	FIGURE 2	Effective
Göbel et al., 1980	Randomized controlled clinical trial	Postpartum shock or respiratory distress	40	Heparin	31.5	Placebo	29.4	NR	OC	FIGURE 2	Neutral
Aoki et al., 2002	Randomized controlled clinical trial	APL, cancer, infection	104	Activated protein C	20.4	Heparin	40	<0.05	JMHW	FIGURE 2	NotEffective
Saito et al., 2007	Randomized controlled clinical trial	Malignancy or infection	224	Recombinant human soluble thrombomodulin	17.2	Heparin	18	>0.05	JMHW	FIGURE 2	Neutral
Aikawa et al., 2011	Retrospective RCT	Infection	80	Thrombomodulin alfa	21.4	Heparin	31.6	NR	JMHW	FIGURE 2	Neutral